Talk about the Latest Alzheimer Research - March 9

No replies

Talk by Stef Heylen, Head of R&D and Chief Medical Officer at Janssen A.I., about the Latest Alzheimer Research on Wednesday, March 9 at 6.30pm, San Francisco.

The Belgian American Chamber of Commerce requests the pleasure of your company to the 1st BelCham event in Silicon Valley: 

“Latest Alzheimer Research” by Stef L.E. Heylen, Head of R&D and Chief Medical Officer at Janssen AI.

Janssen Alzheimer Immunotherapy (Janssen AI) is dedicated to developing treatments for Alzheimer's disease, a degenerative brain disease that has no cure. According to the 2009 World Alzheimer's Report, an estimated 35.6 million people worldwide will be living with dementia in 2010 and this number is expected to nearly double every 20 years. Despite this growth and the far reaching human and financial impact of Alzheimer's disease, there are no currently available treatments that fundamentally change the course of this fatal disease.

Stef has a medical degree from the University of Leuven, Belgium, and has 23+ years experience in drug development in the pharmaceutical industry, obtained at the Janssen Research Foundation, the research division of Janssen Pharmaceutica in Beerse, Belgium. 

Date: Wednesday, March 9, 2011 at 6:30pm

Location: 700 Gateway Blvd, South San Francisco, CA 94080

Sign-up: Please email Claudine Descheemaecker at, please make sure you receive a confirmation email.